The Potential of Psychedelic Healthcare
The Psychedelics as Medicine Report: Fourth Edition
The flagship report has been expanded to include market intelligence on adult-use frameworks in addition to psychedelics as medicine. Insights from business leaders, regulators and researchers empower investors to identify emerging opportunities.
Psychedelic Medicines
- Milestones in psychedelic medicine
- Ketamine
- MDMA
- Psilocybin
- LSD
Psychedelic Research
- Clinical trials
- Scientific papers of note
- Accessing psilocybin in the UK
Intellectual Property
- Patents in psychedelic medicine
Market Sizing
- Ketamine-assisted therapy
- Psilocybin-assisted therapy
- MDMA-assisted therapy
- Adult-use programmes
Regulatory Frameworks
- Oregon Psilocybin Services
- Innovative Licensing and Access Pathway
Healthcare Providers
- Therapist training programmes
Expert Contributors
- Dr Laura Squire OBE - Chief Healthcare Quality and Access Officer, MHRA
- Dr Ben Sessa - Head of Psychedelic Medicine, Awakn Life Sciences
- Angela Allbee MPA - Oregon Psilocybin Services, Oregon Health Authority
- Crispin Blunt MP - Chair at Conservative Drug Policy Reform Group
- Dr Neil Maresky - Chief Executive Officer, Psyence Group
